Dieulafoy’s Lesion, A Rare But Potentially Fatal Cause of Gastrointestinal Bleeding Treated With Repeated Therapeutic Gastroscopies: A Case Report

Gambardella D1,2,*, Schicchi AA2, Luigino Borrello L3, Maria Teresa Caruso MT4 and Tedesco M3

1Department of Medical and Surgical Sciences, University of Catanzaro, Catanzaro, Italy
2Operative Unit of Endoscopy (Director Dr. A.A. Schicchi), “Giovanni Paolo II” Hospital, Lamezia Terme, Italy
3Operative Unit of General Surgery (Director Dr. M. Tedesco), “Giovanni Paolo II” Hospital, Lamezia Terme, Italy
4Medical Intensive Care Unit, “G. Paolo II Hospital”, Lamezia Terme, Italy

*Corresponding author:
Gambardella Denise,
Department of General Surgery,
“G. Paolo II Hospital”,
and Department of General Surgery University of Catanzaro, Italy,
E-mail: gambardelladenise@gmail.com

Received: 01 Nov 2020
Accepted: 16 Nov 2020
Published: 20 Nov 2020

Copyright: ©2020 Gambardella D et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially.


1. Abstract

1.1. Introduction: Dieulafoy’s lesion (DL) is an uncommon but important cause of recurrent upper gastrointestinal bleeding. Advances in endoscopy have increased the detection rate of Dieulafoy’s lesions and have significantly decreased the mortality. Surgical resection was historically the first-line treatment of Dieulafoy’s lesions, usually taking the form of gastrotomy and wide-wedge resection or gastrectomy. This has now been overtaken by advances in endoscopic procedures. Surgical resection is currently reserved for the cases that are refractive to endoscopic or angiographic methods.

1.2. Materials and Methods: we report a case of A 60-year-old male was admitted to our operative unit for a recurrent acute gastrointestinal bleeding hematemesis and melena. He had history of high blood pressure and abuse of NSAIDs. An upper endoscopy revealing a protrusion on the greater curvature just 5 cm below the cardia. The patient underwent four gastroscopies and only the last one was successful in ensuring hemostasis.

1.3. Results: The post-operative period was uneventful and he was discharged seven days after the procedure. The follow-up visit 6 months later showed no complications due to the therapy and no extravasations, ulcerations or any other hemostatic disorders.

1.4. Conclusion: Dieulafoy’s can be successfully managed by endoscopic treatment. Endoscopic hemostasis with combined approaches can be repeated before resorting to surgical resection.

2. Introduction

Dieulafoy’s lesion (DL) also defined as exulceratio simplex, cirsoid aneurysm or caliber-persistent submucosal vessel) is an unusual but important and potentially life threatening cause of gastrointestinal bleeding responsible for up to 5% of acute upper gastrointestinal bleeds [1-3]. The endoscopic modalities for control of bleeding is the first choice of treatment of the lesion, but often the hemostasis is not possible [4]. Angiographic embolization can also be used for therapeutic purposes in patients in whom endoscopic treatment has failed or surgery is contraindicated [5]. A potential emerging approach is EUS-guided therapy [6].

Surgical management is indicated when the lesion fails to respond to therapeutic endoscopy. The endoscopic modalities for control of bleeding is the first choice of treatment of the lesion, but often the hemostasis is not possible. Emergency surgery after the failure of surgical endoscopy, and haemodynamic instability status, is the only choice to solve the bleeding [4]. We describe the case of a patient with recurrent episodes of hematemesis, subjected to 4 egds of which only the last was found to be effective in controlling
hemostasis avoiding the surgical treatment that would have consisted of a total gastrectomy for the position of Dieulafoy lesion.

3. Case Report

A 60-year-old Italian man was admitted to a regional hospital with massive hematemesis and melena. Prior to admission, he had lunch. He was well until he experienced an episode of hematemesis. He had a history of hypertension, and presented in week before intermittent episodes of melena a fever and persistent cough for 7 days treated with antibiotic therapy and non-steroid anti-inflammatory drugs without benefit. There was no history of acid peptic disease, drugs intake, chronic liver disease, or antiplatelet or anticoagulant drugs. He arrived at emergency room with hypotension, severe pallor and tachycardia, and an important hematemesis. On physical examination, he was pale, with a temperature of 37.9°C, a pulse rate of 120 beats per minute, and a blood pressure of 90/52 mmHg. An abdominal examination was unremarkable, and no neurological abnormalities were noted. His laboratory results showed a marked anemia (Hb; 7.5 g/dl) with leukocytosis (16.000/mm3). A blood coagulation test result was also normal. He performs ECG and chest X-ray showing a pneumonia focal thickening in the upper right lobe. He is reassessed for the first emergency EGDS examination that reports only the presence in the stomach of modest blood stagnation of digested blood without signs of bleeding in progress. Therefore, a diagnosis of acute hemorrhagic NSAID abuse gastritis was made. He was admitted to the medical department, He was managed conservatively with H2 blockers, intravenous fluids, kept nil by mouth and blood transfusion. However, during hospitalization, he developed another massive hematemesis; he was subsequently transferred to our department. On admission in our department, his Hb had decreased to 6.0 g/dl. Blood His rapidly progressive anemia associated with massive hematemesis indicated the presence of an active bleeding in his upper GI tract. We performed the second emergency gastroscopy. During gastroscopy were observed fresh blood and a large live clot which did not allowed, despite the patient’s change position, the evaluation of part of the body and gastric fundus, without visible signs of bleeding despite numerous washes of the gastro-duodenal wall. The SNG is repositioned by washing with hot water through the tube and administration of anti-emetic e.v. with repetition of gastroscopy after two hours. After two hours, the patient undergoes a new gastroscopy in which for the first time it is evident at the level of the bottom-gastric passage along the large curve, a small clot adhered to an area of eroded mucosa (3mm), performs infiltration, first perilesional and then intralesional of adrenaline 1: 10,000 (6cc) (Figure a, b and c). The patient at the end of the procedure was hospitalized at the U.O. of General Surgery. Following endoscopic hemostasis, he was initiated on an intravenous proton pump inhibitor, Sondostatin, blood trasfusión, and plasma administration based on blood chemistry parameters. The patient underwent fasting therapy for 72h, and closely monitored the PA of CF every 3 hours for the first 24h. The postoperative course was smooth and uncomplicated. The patient is discharged after 7 days of hospitalization. Close endoscopic follow-up was also recommended. The patient was reassessed at three and six months with endoscopic control, no other acute bleeding episodes have occurred at the time (Figure d).

Figure a: Severe bleeding from Dieulafoy’s lesion and presence of a large clot occupying the gastric lumen.
4. Discussion

The incidence of acute gastrointestinal bleeding ranges from 50 to 150 per 100,000 of the population each year. It is caused by peptic ulcers and esophageal or gastroduodenal erosions in nearly 80% of patients [7]. Dieulafoy’s lesion is a rare and severe case of gastrointestinal bleeding, however, it is not always diagnosable [8, 9]. Histologically it is a normal vessel that has an abnormally large diameter, maintaining a constant width of 1–3 mm that runs inside the submucosa [10]. The incidence and etiology are still uncertain, [11, 12]. There is a common patient profile observed from the various case studies, i.e. male patients with a mean age of 54 years [13-14] with cardiopulmonary comorbidities and chronic renal failure [16]. The stomach is the most common site for Dieulafoy lesion. Mucosal defect most commonly occurs on the minor curve within 6 cm of the gastroesophageal junction [14-17]. However, lesions have been identified throughout the gastrointestinal tract from the esophagus to the anal canal and also of the bronchus [18, 19, 20]. The most common presenting symptom of DL is hematemesis, often massive [21]. DL is usually diagnosed by endoscopic examination, which reveals a pigmented bump from the vessel stump, with minimal surrounding erosion and no ulceration with or without active bleeding or oozing of blood from a tiny point source on the gastrointestinal mucosa [22, 23]. Sometimes repeated gastroscopies are necessary before reaching the definitive diagnosis [24]. From some recent cases the DL can be identified at the first emergency gastroscopy up to 96% of the time [25], this is because most of the time the EGDS they are performed during the active phase of bleeding [26]. Gastroscopy allows hemostasis to be achieved in 93.6% of cases, with a relapse rate of 12.1% [27, 28]. The introduction and improvement of endoscopic techniques have greatly reduced the need to have to resort to surgery, bringing mortality from 80% to 8.6% [17]. Therapeutic gastroscopy is the primary modality of choice in the early stage treatment of Dieulafoy lesion [26]. Therapeutic interventions during gastroscopy consist of: electrocoagulation, sclerotherapy, laser therapy, adrenaline injection, mechanical “clipping” [26]. The adrenaline injection has been used in combination with the other types of treatment reported since, it allows a better visualization of the gastric mucosa and the achievement of therapeutic success [29]. Combined endoscopic therapies are reported to have lower re-bleeding rate when compared to endoscopic monotherapy [16, 30]. Therapeutic gastroscopy allows complete and permanent hemostasis to be achieved in 85% of cases. In 15% of cases in which bleeding occurs, gastroscopic treatment can be retried. In10% can be successfully treated by repeating therapeutic gastroscopy while 5% require definitive surgery [21]. A potential emerging approach is EUS-guided therapy in patients with refractory gastrointestinal bleeding who have failed standard clip, adrenaline and coagulation treatment. This approach has been used to confirm endoscopic hemostasis of DL bleeding, demonstrating no blood flow after.
therapy [4]. Angiographic embolization can also be used for therapeutic purposes in patients in whom endoscopic treatment has failed or surgery is contraindicated [31, 32, 5]. Surgical resection was historically the first-line treatment of Dieulafoy’s lesions, and consisted of a gastrotomy and wide-wedge resection or gastrectomy. With the advancement of technologies in the endoscopic field, surgical resection is currently reserved for the 5% of cases that are refractive to endoscopic or angiographic methods. Laparoscopic surgery is an attractive option for treating these lesions as it offers a cure while being minimally invasive to the patient. However, successful laparoscopic resection relies on accurate pre-operative or intra-operative localization of the bleeding whith clips or tattoo [33].

5. Conclusion
The endoscopic modalities for control of bleeding is the first choice of treatment of the lesion, but often the hemostasis is not effective. We suggest to repeat hemostasis with egds and above all to perform combined approaches before performing a surgery that could consist of a wedge resection or in cases where the lesions is situated within 6 cm of the gastro-esophageal junction a total gastrectomy; a total gastrectomy could be an over treatment for a cause of benign gastric bleeding as DL.

References
28. Park JG, Park JC, Kwon YH, Ahn YS, Seong SW. Endoscopic Man-


